Picton Mahoney Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Picton Mahoney Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$473K	Buy	2,809 +2,800	+31,111%	+$415K	﹤0.01%	791
2026 Q1	$1.19K	Hold	9	–	–	﹤0.01%	1117
2025 Q4	$1.28K	Hold	9	–	–	﹤0.01%	1043
2025 Q3	$1K	Hold	9	–	–	﹤0.01%	974
2025 Q2	$1K	Hold	9	–	–	﹤0.01%	865
2025 Q1	$1K	Hold	9	–	–	﹤0.01%	832
2024 Q4	$1K	Hold	9	–	–	﹤0.01%	744
2024 Q3	$1K	Buy	+9	New	+$1.23K	﹤0.01%	732
2021 Q4	–	Sell	-8,495	Closed	-$816K	–	992
2021 Q3	$816K	Sell	8,495 -950	-10%	-$89.7K	0.03%	563
2021 Q2	$920K	Buy	+9,445	New	+$905K	0.03%	572

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Picton Mahoney Asset Management's NBIX Position: Q2 2026 in Review

Picton Mahoney Asset Management increased its Neurocrine Biosciences (NBIX) stake by 31,111% in Q2 2026, buying an estimated $415K and bringing the position to 2,809 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #791.

Picton Mahoney Asset Management first reported a position in NBIX in Q2 2021 and has held it in 10 quarters since. The position peaked at $920K in Q2 2021. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Picton Mahoney Asset Management held 2,809 shares of Neurocrine Biosciences worth $473K as of Q2 2026.
Picton Mahoney Asset Management bought 2,800 Neurocrine Biosciences shares in Q2 2026, an estimated $415K.
Neurocrine Biosciences made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q2 2026, its #791 holding.
Picton Mahoney Asset Management first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 10 quarters since.
Picton Mahoney Asset Management's Neurocrine Biosciences position peaked at $920K in Q2 2021.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.